Novartis International AG (NOVN) Stock Price, Fundamentals & Analysis

What NOVN does

Novartis International AG (NOVN) researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers products such as Entresto for heart failure, Cosentyx for psoriasis and related conditions, Kisqali for certain cancers, Promacta/Revolade for blood disorders, Tafinlar+Mekinist for oncology, and Jakavi for myelofibrosis and related diseases. It is listed on the SIX Swiss Exchange and is a major peer alongside companies like Roche Holding AG (ROP) and Alcon Inc (ALC).

Key numbers explained

• The current price is 119,8 CHF, reflecting what investors pay for one share today.
• The trailing P/E ratio of 21,9 shows how much the market is willing to pay per unit of recent earnings; a lower figure can suggest a more attractive entry point relative to earnings.
• The forward P/E ratio of 14,7 uses expected future earnings, often giving a clearer picture of valuation than the trailing number alone.
• The dividend yield of 3,09% indicates the annual dividend as a percentage of the current price, a common measure for income-focused investors.
• The ex-dividend date of 10 mar. 2026 is the cutoff: buying before this date qualifies you for the next dividend payment.
• A beta of 0,49 suggests the stock has historically moved about half as much as the broader market, a sign of lower volatility.
• The debt-to-equity ratio of 116,9% means the company carries more debt than equity, which is typical for large pharmaceutical firms but worth monitoring.
• The price-to-book ratio of 6,64 compares the market price to the company's book value per share, a way to gauge whether the market values the firm above or below its accounting net assets.

What to watch

Novartis International AG (NOVN) is part of the Healthcare sector and the Drug Manufacturers - General industry, which are sensitive to drug approvals, patent expirations, and regulatory changes. Investors often track the pipeline of new medicines, competitive dynamics with peers such as Bayer (BAYN), and currency movements since the company reports in USD while trading in CHF. The next earnings report on 27 oct. 2026 will provide updated guidance on revenue and profit trends.